The impact of cerebrovascular lesions in Alzheimer disease--a comparative autopsy study

Kurt A Jellinger1, Erich Mitter-Ferstl

  • 1Institute of Clinical Neurobiology, Kenyongasse 18, 1070 Vienna, Austria. kurt.jellinger@univie.ac.at

Journal of Neurology
|September 25, 2003
PubMed

Insights

Alzheimer disease (AD) brains show significantly more cerebrovascular lesions, including infarcts and hemorrhages, than control brains. This suggests a higher risk of stroke in individuals with AD.

Area of Science:

  • Neuropathology
  • Neurodegenerative Diseases
  • Cerebrovascular Diseases

Background:

  • Epidemiological and clinico-pathological data suggest overlaps between Alzheimer disease (AD) and cerebrovascular pathology.
  • Previous studies on the relationship between AD and cerebrovascular lesions have yielded controversial results.

Purpose of the Study:

  • To compare the frequency of cerebral infarcts, hemorrhages, and minor cerebrovascular lesions in autopsy-proven Alzheimer disease (AD) cases versus age-matched controls.

Main Methods:

  • Comparison of 730 autopsy-proven AD cases with 535 age-matched controls.
  • Utilized routine and immunohistochemical methods for pathological assessment.

Main Results:

  • Cerebrovascular pathology was significantly more prevalent in AD brains (48.0%) compared to controls (32.8%).
  • Minor to moderate lesions (lacunes, amyloid angiopathy) and severe lesions (infarcts, hemorrhages) were more frequent in AD.
  • Acute and old cerebral hemorrhages correlated significantly with severe amyloid angiopathy.

Conclusions:

  • The study indicates a higher incidence of cerebrovascular lesions in Alzheimer disease (AD).
  • Individuals with AD may have greater susceptibility to stroke.
  • Further prospective clinicopathological studies are warranted to confirm these findings.
Abstract

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...